Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt repayments

Daily Values

Others

Leases Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments R&D In Process Receivables - Net Shares Issued Shares Outstanding Shares Outstanding Short-Term Debt repayments

Ratios

Immunovant (IMVT) Long-Term Debt Issuances (2019 - 2020)

Immunovant filings provide 2 years of Long-Term Debt Issuances readings, the most recent being $27.1 million for Q1 2020.

Quarterly Long-Term Debt Issuances changed N/A to $27.1 million in Q1 2020 from the year-ago period, while the trailing twelve-month figure was $27.1 million through Dec 2020, changed N/A year-over-year, with the annual reading at $35.0 million for FY2020, N/A changed from the prior year.
Long-Term Debt Issuances hit $27.1 million in Q1 2020 for Immunovant, up from -$27.1 million in the prior quarter.
Across five years, Long-Term Debt Issuances topped out at $27.1 million in Q1 2020 and bottomed at -$27.1 million in Q4 2019.